A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2017
At a glance
- Drugs NKTR 181 (Primary)
- Indications Musculoskeletal pain; Pain
- Focus Registrational; Therapeutic Use
- Acronyms SUMMIT-07
- Sponsors Nektar Therapeutics
- 06 Sep 2017 According to a Nektar Therapeutics media release, data from the study has been presented at the 2017 PAINWeek Conference.
- 06 Sep 2017 Results presented in a Nektar Therapeutics media release.
- 30 Aug 2017 According to a Nektar Therapeutics media release, dat will be presented at the upcoming 2017 PAINWeek Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History